Gyre Therapeutics (NASDAQ:GYRE) Sets New 1-Year Low – Here’s What Happened

Gyre Therapeutics, Inc. (NASDAQ:GYRE)’s stock price hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $5.87 and last traded at $5.94, with a volume of 125877 shares trading hands. The stock had previously closed at $6.06.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Zacks Research lowered Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, March 16th. Weiss Ratings lowered Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Finally, Wall Street Zen lowered Gyre Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Two investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Gyre Therapeutics has a consensus rating of “Hold” and a consensus target price of $17.00.

Gyre Therapeutics Price Performance

The business has a fifty day moving average price of $7.18 and a two-hundred day moving average price of $7.58. The firm has a market capitalization of $576.36 million, a price-to-earnings ratio of -65.99 and a beta of 2.03.

Gyre Therapeutics (NASDAQ:GYRE) last announced its quarterly earnings data on Thursday, March 12th. The company reported $0.04 earnings per share for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04). The firm had revenue of $37.20 million during the quarter, compared to analyst estimates of $36.30 million. Gyre Therapeutics had a negative net margin of 5.44% and a positive return on equity of 3.13%. On average, research analysts predict that Gyre Therapeutics, Inc. will post -0.3 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Ying Luo sold 10,136 shares of the business’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $8.04, for a total transaction of $81,493.44. Following the completion of the transaction, the chief executive officer directly owned 2,565,226 shares in the company, valued at $20,624,417.04. The trade was a 0.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Weiguo Ye sold 12,820 shares of the business’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $6.15, for a total transaction of $78,843.00. Following the transaction, the chief operating officer owned 700,000 shares of the company’s stock, valued at $4,305,000. This represents a 1.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 32,535 shares of company stock valued at $219,580 over the last 90 days. 10.00% of the stock is currently owned by insiders.

Institutional Trading of Gyre Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of GYRE. Bank of America Corp DE grew its holdings in Gyre Therapeutics by 28.8% during the second quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock worth $46,000 after acquiring an additional 1,402 shares during the period. JPMorgan Chase & Co. grew its holdings in Gyre Therapeutics by 84.6% during the second quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after acquiring an additional 2,961 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Gyre Therapeutics by 77.8% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock worth $54,000 after acquiring an additional 3,244 shares during the period. Dimensional Fund Advisors LP acquired a new stake in Gyre Therapeutics during the fourth quarter worth about $77,000. Finally, Wells Fargo & Company MN grew its holdings in Gyre Therapeutics by 132.4% during the fourth quarter. Wells Fargo & Company MN now owns 12,919 shares of the company’s stock worth $91,000 after acquiring an additional 7,361 shares during the period. 23.99% of the stock is owned by institutional investors and hedge funds.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.